{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:59:34Z","timestamp":1791280774648,"version":"4.1.0"},"reference-count":166,"publisher":"American Association for Cancer Research (AACR)","issue":"4","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Much has been learned regarding the biology and clinical implications of genetic abnormalities in multiple myeloma. Because of recent advances in the field, an International Workshop was held in Paris in February of 2003. This summary describes the consensus recommendations arising from that meeting with special emphasis on novel genetic observations. For instance, it is increasingly clear that translocations involving the immunoglobulin heavy-chain locus are important for the pathogenesis of one-half of patients. As a corollary, it also clear that the remaining patients, lacking IgH translocations, have hyperdiploidy as the hallmark of their disease. Several important genetic markers are associated with a shortened survival such as chromosome 13 monosomy, hypodiploidy, and others. The events leading the transformation of the monoclonal gammopathy of undetermined significance (MGUS) to myeloma are still unclear. One of the few differential genetic lesions between myeloma and MGUS is the presence of ras mutations in the latter. Gene expression platforms are capable of detecting many of the genetic aberrations found in the clonal cells of myeloma. Areas in need of further study were identified. The study of the genetic aberrations will likely form the platform for targeted therapy for the disease.<\/jats:p>","DOI":"10.1158\/0008-5472.can-03-2876","type":"journal-article","created":{"date-parts":[[2005,9,20]],"date-time":"2005-09-20T22:37:24Z","timestamp":1127255844000},"page":"1546-1558","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":557,"title":["Genetics and Cytogenetics of Multiple Myeloma"],"prefix":"10.1158","volume":"64","author":[{"given":"Rafael","family":"Fonseca","sequence":"first","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, Minnesota;"},{"name":"11Division of Hematology and Oncology, Mayo Clinic, Scottsdale, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Barlogie","sequence":"additional","affiliation":[{"name":"2University of Arkansas for Medical Science, Little Rock, Arkansas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regis","family":"Bataille","sequence":"additional","affiliation":[{"name":"3Institute of Biology, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Bastard","sequence":"additional","affiliation":[{"name":"3Institute of Biology, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Leif","family":"Bergsagel","sequence":"additional","affiliation":[{"name":"4Cornell Medical Center, New York, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Chesi","sequence":"additional","affiliation":[{"name":"4Cornell Medical Center, New York, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith E.","family":"Davies","sequence":"additional","affiliation":[{"name":"5University of Leeds and Leeds General Infirmary, Leeds, West Yorkshire, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Drach","sequence":"additional","affiliation":[{"name":"6University of Vienna, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip R.","family":"Greipp","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan R.","family":"Kirsch","sequence":"additional","affiliation":[{"name":"7National Cancer Institute, NIH, Bethesda, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Michael","family":"Kuehl","sequence":"additional","affiliation":[{"name":"7National Cancer Institute, NIH, Bethesda, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus M.","family":"Hernandez","sequence":"additional","affiliation":[{"name":"8Hospital Universitario de Salamanca, Salamanca, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Minvielle","sequence":"additional","affiliation":[{"name":"3Institute of Biology, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda M.","family":"Pilarski","sequence":"additional","affiliation":[{"name":"9University of Alberta, Edmonton, Alberta, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"John D.","family":"Shaughnessy","sequence":"additional","affiliation":[{"name":"2University of Arkansas for Medical Science, Little Rock, Arkansas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Keith","family":"Stewart","sequence":"additional","affiliation":[{"name":"10Princess Margaret Hospital, Toronto, Ontario, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Avet-Loiseau","sequence":"additional","affiliation":[{"name":"3Institute of Biology, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2004,2,18]]},"reference":[{"key":"2022061620194287500_B1","doi-asserted-by":"crossref","unstructured":"Dewald G. W., Kyle R. A., Hicks G. A., Greipp P. R. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma. plasma cell leukemia, or amyloidosis. Blood, 66:\u2008380-390, \u20081985.","DOI":"10.1182\/blood.V66.2.380.bloodjournal662380"},{"key":"2022061620194287500_B2","doi-asserted-by":"crossref","unstructured":"Zandecki M., Lai J. L., Facon T. Multiple myeloma: almost all patients are cytogenetically abnormal. Br. J. Haematol., 94:\u2008217-227, \u20081996.","DOI":"10.1046\/j.1365-2141.1996.d01-2939.x"},{"key":"2022061620194287500_B3","unstructured":"Tabernero D., San Miguel J. F., Garcia-Sanz M., Najera L., Garcia-Isidoro M., Perez-Simon J. A., Gonzalez M., Wiegant J., Raap A. K., Orfao A. Incidence of chromosome numerical changes in multiple myeloma: fluorescence in situ hybridization analysis using 15 chromosome-specific probes. Am. J. Pathol., 149:\u2008153-161, \u20081996."},{"key":"2022061620194287500_B4","doi-asserted-by":"crossref","unstructured":"Avet-Loiseau H., Facon T., Grosbois B., Magrangeas F., Rapp M. J., Harousseau J. L., Minvielle S., Bataille R., Intergroupe Francophone du Myelome. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood, 99:\u20082185-2191, \u20082002.","DOI":"10.1182\/blood.V99.6.2185"},{"key":"2022061620194287500_B5","unstructured":"Drach J., Schuster J., Nowotny H., Angerler J., Rosenthal F., Fiegl M., Rothermundt C., Gsur A., Jager U., Heinz R., Lechner K., Ludwig H., Huber H. Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Res., 55:\u20083854-3859, \u20081995."},{"key":"2022061620194287500_B6","unstructured":"Fonseca R., Ahmann G. J., Juneau A. L., Jalal S. M., Dewald G. W., Larson D. M., Therneau T. M., Gertz M. A., Greipp P. R. Cytogenetic abnormalities in multiple myeloma and related plasma cell disorders; a comparison of conventional cytogenetic analysis to fluorescent in-situ hybridization with simultaneous cytoplasmic immunoglobulin staining. Blood, 90:\u2008349(Meeting Abstract)\u20081997."},{"key":"2022061620194287500_B7","doi-asserted-by":"crossref","unstructured":"Fonseca R., Bailey R. J., Ahmann G. J., Rajkumar S. V., Hoyer J. D., Lust J. A., Kyle R. A., Gertz M. A., Greipp P. R., Dewald G. W. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood, 100:\u20081417-1424, \u20082002.","DOI":"10.1182\/blood.V100.4.1417.h81602001417_1417_1424"},{"key":"2022061620194287500_B8","doi-asserted-by":"crossref","unstructured":"Kuehl W. M., Bergsagel P. L. Multiple myeloma: evolving genetic events and host interactions. Nat. Rev Cancer, 2:\u2008175-187, \u20082002.","DOI":"10.1038\/nrc746"},{"key":"2022061620194287500_B9","doi-asserted-by":"crossref","unstructured":"Bergsagel P. L., Kuehl W. M. Chromosome translocations in multiple myeloma. Oncogene, 20:\u20085611-5622, \u20082001.","DOI":"10.1038\/sj.onc.1204641"},{"key":"2022061620194287500_B10","doi-asserted-by":"crossref","unstructured":"Tricot G., Barlogie B., Jagannath S., Bracy D., Mattox S., Vesole D. H., Naucke S., Sawyer J. R. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood, 86:\u20084250-4256, \u20081995.","DOI":"10.1182\/blood.V86.11.4250.bloodjournal86114250"},{"key":"2022061620194287500_B11","doi-asserted-by":"crossref","unstructured":"Smadja N. V., Bastard C., Brigaudeau C., Leroux D., Fruchart C. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood, 98:\u20082229-2238, \u20082001.","DOI":"10.1182\/blood.V98.7.2229"},{"key":"2022061620194287500_B12","doi-asserted-by":"crossref","unstructured":"Smadja N. V., Fruchart C., Isnard F., Louvet C., Dutel J. L., Cheron N., Grange M. J., Monconduit M., Bastard C. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia (Baltimore), 12:\u2008960-969, \u20081998.","DOI":"10.1038\/sj.leu.2401041"},{"key":"2022061620194287500_B13","doi-asserted-by":"crossref","unstructured":"Seong C., Delasalle K., Hayes K., Weber D., Dimopoulos M., Swantkowski J., Huh Y., Glassman A., Champlin R., Alexanian R. Prognostic value of cytogenetics in multiple myeloma. Br. J. Haematol., 101:\u2008189-194, \u20081998.","DOI":"10.1046\/j.1365-2141.1998.00657.x"},{"key":"2022061620194287500_B14","doi-asserted-by":"crossref","unstructured":"Kyle R. A., Therneau T. M., Rajkumar S. V., Offord J. R., Larson D. R., Plevak M. F., Melton L. J., III. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N. Eng. J. Med., 346:\u2008564-569, [See comments.]\u20082002.","DOI":"10.1056\/NEJMoa01133202"},{"key":"2022061620194287500_B15","doi-asserted-by":"crossref","unstructured":"International-Myeloma-Working-Group Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br. J. Haematol., 121:\u2008749-757, \u20082003.","DOI":"10.1046\/j.1365-2141.2003.04355.x"},{"key":"2022061620194287500_B16","doi-asserted-by":"crossref","unstructured":"Rajkumar S. V., Fonseca R., Dewald G. W., Therneau T. M., Lacy M. Q., Kyle R. A., Greipp P. R., Gertz M. A. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet., 113:\u200873-77, \u20081999.","DOI":"10.1016\/S0165-4608(99)00009-6"},{"key":"2022061620194287500_B17","doi-asserted-by":"crossref","unstructured":"Cesana C., Klersy C., Barbarano L., Nosari A. M., Crugnola M., Pungolino E., Gargantini L., Granata S., Valentini M., Morra E. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J. Clin. Oncol., 20:\u20081625-1634, \u20082002.","DOI":"10.1200\/JCO.2002.20.6.1625"},{"key":"2022061620194287500_B18","unstructured":"Salmon S. Immunoglobulin synthesis and tumor kinetics of multiple myeloma. Semin. Hematol., 10:\u2008135-147, \u20081973."},{"key":"2022061620194287500_B19","unstructured":"Bergsagel D. The incidence and epidemiology of plasma cell neoplasms. Stem Cells (Dayton), 13 (Suppl. 2):\u20081-9, \u20081995."},{"key":"2022061620194287500_B20","unstructured":"Avet-Loiseau H., Facon T., Daviet A., Godon C., Rapp M. J., Harousseau J. L., Grosbois B., Bataille R. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Res., 59:\u20084546-4550, \u20081999."},{"key":"2022061620194287500_B21","doi-asserted-by":"crossref","unstructured":"Drach J., Angerler J., Schuster J., Rothermundt C., Thalhammer R., Haas O. A., Jager U., Fiegl M., Geissler K., Ludwig H. Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood, 86:\u20083915-3921, \u20081995.","DOI":"10.1182\/blood.V86.10.3915.bloodjournal86103915"},{"key":"2022061620194287500_B22","doi-asserted-by":"crossref","unstructured":"Zandecki M., Obein V., Bernardi F., Soenen V., Flactif M., Lai J. L., Francois M., Facon T. Monoclonal gammopathy of undetermined significance: chromosome changes are a common finding within bone marrow plasma cells. Br. J. Haematol., 90:\u2008693-696, \u20081995.","DOI":"10.1111\/j.1365-2141.1995.tb05602.x"},{"key":"2022061620194287500_B23","doi-asserted-by":"crossref","unstructured":"Rasillo A., Tabernero M. D., Sanchez M. L., Perez de Andres M., Martin Ayuso M., Hernandez J., Moro M. J., Fernandez-Calvo J., Sayagues J. M., Bortoluci A., San Miguel J. F., Orfao A. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia. Cancer (Phila.), 97:\u2008601-609, \u20082003.","DOI":"10.1002\/cncr.11100"},{"key":"2022061620194287500_B24","doi-asserted-by":"crossref","unstructured":"Kyle R. A., Garton J. P. The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo Clin. Proc., 62:\u2008719-731, \u20081987.","DOI":"10.1016\/S0025-6196(12)65225-2"},{"key":"2022061620194287500_B25","doi-asserted-by":"crossref","unstructured":"Kyle R. A., Greipp P. R. Smoldering multiple myeloma. N. Engl. J. Med., 302:\u20081347-1349, \u20081980.","DOI":"10.1056\/NEJM198006123022405"},{"key":"2022061620194287500_B26","doi-asserted-by":"crossref","unstructured":"Witzig T. E., Kyle R. A., O\u2019Fallon W. M., Greipp P. R. Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma. Br. J. Haematol., 87:\u2008266-272, \u20081994.","DOI":"10.1111\/j.1365-2141.1994.tb04908.x"},{"key":"2022061620194287500_B27","doi-asserted-by":"crossref","unstructured":"Blade J., Lopez G. A., Rozman C., Cervantes F., Salgado C., Aguilar J. L., Vives C. J. L., Montserrat E. Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. Br. J. Haematol., 81:\u2008391-394, \u20081992.","DOI":"10.1111\/j.1365-2141.1992.tb08245.x"},{"key":"2022061620194287500_B28","doi-asserted-by":"crossref","unstructured":"Bataille R., Harousseau J. L. Multiple myeloma. N. Engl. J. Med., 336:\u20081657-1664, \u20081997.","DOI":"10.1056\/NEJM199706053362307"},{"key":"2022061620194287500_B29","doi-asserted-by":"crossref","unstructured":"Avet-Loiseau H., Li J. Y., Morineau N., Facon T., Brigaudeau C., Harousseau J. L., Grosbois B., Bataille R. Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myelome. Blood, 94:\u20082583-2589, \u20081999.","DOI":"10.1182\/blood.V94.8.2583.420a05_2583_2589"},{"key":"2022061620194287500_B30","doi-asserted-by":"crossref","unstructured":"Colls B. M. Monoclonal gammopathy of undetermined significance (MGUS)-31 year follow up of a community study. Aust. N. Z. J. Med., 29:\u2008500-504, \u20081999.","DOI":"10.1111\/j.1445-5994.1999.tb00750.x"},{"key":"2022061620194287500_B31","doi-asserted-by":"crossref","unstructured":"Zhan F., Tian E., Bumm K., Smith R., Barlogie B., Shaughnessy J., Jr. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood, 101:\u20081128-1140, \u20082003.","DOI":"10.1182\/blood-2002-06-1737"},{"key":"2022061620194287500_B32","doi-asserted-by":"crossref","unstructured":"Jourdan M., Ferlin M., Legouffe E., Horvathova M., Liautard J., Rossi J. F., Wijdenes J., Brochier J., Klein B. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br. J. Haematol., 100:\u2008637-646, \u20081998.","DOI":"10.1046\/j.1365-2141.1998.00623.x"},{"key":"2022061620194287500_B33","doi-asserted-by":"crossref","unstructured":"Ahmann G. J., Jalal S. M., Juneau A. L., Christensen E. R., Hanson C. A., Dewald G. W., Greipp P. R. A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. Cancer Genet Cytogenet., 101:\u20087-11, \u20081998.","DOI":"10.1016\/S0165-4608(97)00058-7"},{"key":"2022061620194287500_B34","doi-asserted-by":"crossref","unstructured":"Lai J. L., Zandecki M., Mary J. Y., Bernardi F., Izydorczyk V., Flactif M., Morel P., Jouet J. P., Bauters F., Facon T. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood, 85:\u20082490-2497, [Review]\u20081995.","DOI":"10.1182\/blood.V85.9.2490.bloodjournal8592490"},{"key":"2022061620194287500_B35","doi-asserted-by":"crossref","unstructured":"Gould J., Alexanian R., Goodacre A., Pathak S., Hecht B., Barlogie B. Plasma cell karyotype in multiple myeloma. Blood, 71:\u2008453-456, \u20081988.","DOI":"10.1182\/blood.V71.2.453.bloodjournal712453"},{"key":"2022061620194287500_B36","doi-asserted-by":"crossref","unstructured":"Zandecki M. Multiple-myeloma\u2014almost all patients are cytogenetically abnormal. Br. J. Haematol., 94:\u2008217-227, \u20081996.","DOI":"10.1046\/j.1365-2141.1996.d01-2939.x"},{"key":"2022061620194287500_B37","doi-asserted-by":"crossref","unstructured":"Sawyer J. R., Waldron J. A., Jagannath S., Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet., 82:\u200841-49, \u20081995.","DOI":"10.1016\/0165-4608(94)00284-I"},{"key":"2022061620194287500_B38","doi-asserted-by":"crossref","unstructured":"Debes-Marun C., Dewald G., Bryant S., Picken E., Santana-Da\u0301vila S., Gonza\u0301lez-Paz N., Winkler J. M., Kyle R., Gertz M., Witzig T., Dispenzieri A., Lacy M., Rajkumar S., Lust J., Greipp P., Fonseca R. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia (Baltimore), 17:\u2008427-436, \u20082003.","DOI":"10.1038\/sj.leu.2402797"},{"key":"2022061620194287500_B39","doi-asserted-by":"crossref","unstructured":"Chesi M., Nardini E., Brents L. A., Schrock E., Ried T., Kuehl W. M., Bergsagel P. L. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat. Genet., 16:\u2008260-264, \u20081997.","DOI":"10.1038\/ng0797-260"},{"key":"2022061620194287500_B40","doi-asserted-by":"crossref","unstructured":"Chesi M., Bergsagel P. L., Shonukan O. O., Martelli M. L., Brents L. A., Chen T., Schrock E., Ried T., Kuehl W. M. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood, 91:\u20084457-4463, \u20081998.","DOI":"10.1182\/blood.V91.12.4457.412k48_4457_4463"},{"key":"2022061620194287500_B41","doi-asserted-by":"crossref","unstructured":"Sawyer J. R., Lukacs J. L., Munshi N., Desikan K. R., Singhal S., Mehta J., Siegel D., Shaughnessy J., Barlogie B. Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. Blood, 92:\u20084269-4278, \u20081998.","DOI":"10.1182\/blood.V92.11.4269.423k31_4269_4278"},{"key":"2022061620194287500_B42","doi-asserted-by":"crossref","unstructured":"Sawyer J. R., Lukacs J. L., Thomas E. L., Swanson C. M., Goosen L. S., Sammartino G., Gilliland J. C., Munshi N. C., Tricot G., Shaughnessy J. D., Jr., Barlogie B. Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma. Br. J. Haematol., 112:\u2008167-174, \u20082001.","DOI":"10.1046\/j.1365-2141.2001.02546.x"},{"key":"2022061620194287500_B43","unstructured":"Rao P. H., Cigudosa J. C., Ning Y., Calasanz M. J., Iida S., Tagawa S., Michaeli J., Klein B., Dalla-Favera R., Jhanwar S. C., Ried T., Chaganti R. S. Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma. Blood, 92:\u20081743-1748, \u20081998."},{"key":"2022061620194287500_B44","doi-asserted-by":"crossref","unstructured":"Avet-Loiseau H., Bataille R. Detection of nonrandom chromosomal changes in multiple myeloma by comparative genomic hybridization. Blood, 92:\u20082997-2998, \u20081998.","DOI":"10.1182\/blood.V92.8.2997.splL15_2997_2998"},{"key":"2022061620194287500_B45","doi-asserted-by":"crossref","unstructured":"Cigudosa J. C., Rao P. H., Calasanz M. J., Odero M. D., Michaeli J., Jhanwar S. C., Chaganti R. S. Characterization of nonrandom chromosomal gains and losses in multiple myeloma by comparative genomic hybridization. Blood, 91:\u20083007-3010, \u20081998.","DOI":"10.1182\/blood.V91.8.3007.3007_3007_3010"},{"key":"2022061620194287500_B46","doi-asserted-by":"crossref","unstructured":"Gutierrez N. C., Hernandez J. M., Garcia J. L., Canizo M. C., Gonzalez M., Hernandez J., Gonzalez M. B., Garcia-Marcos M. A., San Miguel J. F. Differences in genetic changes between multiple myeloma and plasma cell leukemia demonstrated by comparative genomic hybridization. Leukemia (Baltimore), 15:\u2008840-845, \u20082001.","DOI":"10.1038\/sj.leu.2402116"},{"key":"2022061620194287500_B47","doi-asserted-by":"crossref","unstructured":"Avet-Loiseau H., Andree-Ashley L. E., Moore D., II, Mellerin M. P., Feusner J., Bataille R., Pallavicini M. G. Molecular cytogenetic abnormalities in multiple myeloma and plasma cell leukemia measured using comparative genomic hybridization. Genes Chromosomes Cancer, 19:\u2008124-133, \u20081997.","DOI":"10.1002\/(SICI)1098-2264(199706)19:2<124::AID-GCC8>3.0.CO;2-0"},{"key":"2022061620194287500_B48","doi-asserted-by":"crossref","unstructured":"Hayman S. R., Bailey R. J., Jalal S. M., Ahmann G. J., Dispenzieri A., Gertz M. A., Greipp P. R., Kyle R. A., Lacy M. Q., Rajkumar V., Witzig T. E., Lust J. A., Fonseca R. Translocations involving heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. Blood, 98:\u20082266-2268, \u20082001.","DOI":"10.1182\/blood.V98.7.2266"},{"key":"2022061620194287500_B49","doi-asserted-by":"crossref","unstructured":"Fonseca R., Harrington D., Oken M., Kyle R., Dewald G., Bailey R., Van Wier S., Henderson K., Hoyer J., Blood E., Kay N., Van Ness B., Greipp P. Myeloma and the t(11;14)(q13;q32) represents a uniquely defined biological subset of patients. Blood, 99:\u20083735-3741, \u20082002.","DOI":"10.1182\/blood.V99.10.3735"},{"key":"2022061620194287500_B50","unstructured":"Fonseca R., Harrington D., Oken M., Dewald G., Bailey R., Van Wier S., Henderson K., Blood E., Rajkumar S., Kay N., Van Ness B., Greipp P. Biologic and prognostic significance of interphase FISH detection of chromosome 13 abnormalities (\u039413) in multiple myeloma: an Eastern Cooperative Oncology Group (ECOG) Study. Cancer Res., 62:\u2008715-720, \u20082002."},{"key":"2022061620194287500_B51","doi-asserted-by":"crossref","unstructured":"Fonseca R., Oken M., Greipp P. The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathies of undetermined significance. Blood, 98:\u20081271-1272, \u20082001.","DOI":"10.1182\/blood.V98.4.1271"},{"key":"2022061620194287500_B52","doi-asserted-by":"crossref","unstructured":"Fonseca R., Oken M., Harrington D., Bailey R., Van Wier S., Henderson K., Kay N., Van Ness B., Greipp P., Dewald G. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q-arm or monosomy. Leukemia (Baltimore), 15:\u2008981-986, \u20082001.","DOI":"10.1038\/sj.leu.2402125"},{"key":"2022061620194287500_B53","doi-asserted-by":"crossref","unstructured":"Fonseca R., Blood E., Rue M., Harrington D., Oken M. M., Kyle R. A., Dewald G. W., Van Ness B., Van Wier S. A., Henderson K. J., Bailey R. J., Greipp P. R. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood, 101:\u20084569-4575, \u20082003.","DOI":"10.1182\/blood-2002-10-3017"},{"key":"2022061620194287500_B54","doi-asserted-by":"crossref","unstructured":"Avet-Loiseau H., Brigaudeau C., Morineau N., Talmant P., Lai J. L., Daviet A., Li J. Y., Praloran V., Rapp M. J., Harousseau J. L., Facon T., Bataille R. High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization. Genes Chromosomes Cancer, 24:\u20089-15, \u20081999.","DOI":"10.1002\/(SICI)1098-2264(199901)24:1<9::AID-GCC2>3.0.CO;2-K"},{"key":"2022061620194287500_B55","doi-asserted-by":"crossref","unstructured":"Avet-Loiseau H., Daviet A., Saunier S., Bataille R. Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. Br. J. Haematol., 111:\u20081116-1117, \u20082000.","DOI":"10.1046\/j.1365-2141.2000.02488.x"},{"key":"2022061620194287500_B56","unstructured":"Avet-Loiseau H., Li J. Y., Facon T., Brigaudeau C., Morineau N., Maloisel F., Rapp M. J., Talmant P., Trimoreau F., Jaccard A., Harousseau J. L., Bataille R. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32). Cancer Res., 58:\u20085640-5645, \u20081998."},{"key":"2022061620194287500_B57","doi-asserted-by":"crossref","unstructured":"Konigsberg R., Ackermann J., Kaufmann H., Zojer N., Urbauer E., Kromer E., Jager U., Gisslinger H., Schreiber S., Heinz R., Ludwig H., Huber H., Drach J. Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance. Leukemia (Baltimore), 14:\u20081975-1979, \u20082000.","DOI":"10.1038\/sj.leu.2401909"},{"key":"2022061620194287500_B58","doi-asserted-by":"crossref","unstructured":"Fonseca R., Ahmann G. J., Jalal S. M., Dewald G. W., Larson D. R., Therneau T. M., Gertz M. A., Kyle R. A., Greipp P. R. Chromosomal abnormalities in systemic amyloidosis. Br. J. Haematol., 103:\u2008704-710, \u20081998.","DOI":"10.1046\/j.1365-2141.1998.01034.x"},{"key":"2022061620194287500_B59","doi-asserted-by":"crossref","unstructured":"Gabrea A., Bergsagel P. L., Chesi M., Shou Y., Kuehl W. M. Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell. Mol. Cell, 3:\u2008119-123, \u20081999.","DOI":"10.1016\/S1097-2765(00)80180-X"},{"key":"2022061620194287500_B60","doi-asserted-by":"crossref","unstructured":"Keats J. J., Reiman T., Maxwell C. A., Taylor B. J., Larratt L. M., Mant M. J., Belch A. R., Pilarski L. M. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood, 101:\u20081520-1529, \u20082003.","DOI":"10.1182\/blood-2002-06-1675"},{"key":"2022061620194287500_B61","doi-asserted-by":"crossref","unstructured":"Santra M., Zhan F., Tian E., Barlogie B., Shaughnessy J., Jr. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH\/MMSET fusion transcript. Blood, 101:\u20082374-2376, \u20082003.","DOI":"10.1182\/blood-2002-09-2801"},{"key":"2022061620194287500_B62","doi-asserted-by":"crossref","unstructured":"Zhan F., Hardin J., Kordsmeier B., Bumm K., Zheng M., Tian E., Sanderson R., Yang Y., Wilson C., Zangari M., Anaissie E., Morris C., Muwalla F., van Rhee F., Fassas A., Crowley J., Tricot G., Barlogie B., Shaughnessy J., Jr. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood, 99:\u20081745-1757, \u20082002.","DOI":"10.1182\/blood.V99.5.1745"},{"key":"2022061620194287500_B63","doi-asserted-by":"crossref","unstructured":"De Vos J., Couderc G., Tarte K., Jourdan M., Requirand G., Delteil M-C., Rossi J-F., Mechti N., Klein B. Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood, 98:\u2008771-780, \u20082001.","DOI":"10.1182\/blood.V98.3.771"},{"key":"2022061620194287500_B64","doi-asserted-by":"crossref","unstructured":"Tarte K., De Vos J., Thykjaer T., Zhan F., Fiol G., Costes V., Reme T., Legouffe E., Rossi J. F., Shaughnessy J., Jr., Orntoft T. F., Klein B. Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood, 100:\u20081113-1122, [See comments.]\u20082002.","DOI":"10.1182\/blood.V100.4.1113.h81602001113_1113_1122"},{"key":"2022061620194287500_B65","doi-asserted-by":"crossref","unstructured":"Claudio J. O., Masih-Khan E., Tang H., Goncalves J., Voralia M., Li Z. H., Nadeem V., Cukerman E., Francisco-Pabalan O., Liew C. C., Woodgett J. R., Stewart A. K. A molecular compendium of genes expressed in multiple myeloma. Blood, 100:\u20082175-2186, \u20082002.","DOI":"10.1182\/blood-2002-01-0008"},{"key":"2022061620194287500_B66","doi-asserted-by":"crossref","unstructured":"Magrangeas F., Nasser V., Avet-Loiseau H., Loriod B., Decaux O., Granjeaud S., Bertucci F., Birnbaum D., Nguyen C., Harousseau J-L., Bataille R., Houlgatte R., Minvielle S. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood, 101:\u20084998-5006, \u20082003.","DOI":"10.1182\/blood-2002-11-3385"},{"key":"2022061620194287500_B67","doi-asserted-by":"crossref","unstructured":"Latreille J., Barlogie B., Johnston D., Drewinko B., Alexanian R. Ploidy and proliferative characteristics in monoclonal gammopathies. Blood, 59:\u200843-51, \u20081982.","DOI":"10.1182\/blood.V59.1.43.43"},{"key":"2022061620194287500_B68","doi-asserted-by":"crossref","unstructured":"Zandecki M., Bernardi F., Lai J., Facon T., Izydorczyk V., Bauters F., Cosson A. Image analysis in multiple myeloma at diagnosis. Correlation with cytogenetic study. Cancer Genet. Cytogenet., 74:\u2008115-119, \u20081994.","DOI":"10.1016\/0165-4608(94)90008-6"},{"key":"2022061620194287500_B69","doi-asserted-by":"crossref","unstructured":"Zandecki M., Lai J. L., Genevieve F., Bernardi F., Volle-Remy H., Blanchet O., Francois M., Cosson A., Bauters F., Facon T. Several cytogenetic subclones may be identified within plasma cells from patients with monoclonal gammopathy of undetermined significance, both at diagnosis and during the indolent course of this condition. Blood, 90:\u20083682-3690, \u20081997.","DOI":"10.1182\/blood.V90.9.3682"},{"key":"2022061620194287500_B70","doi-asserted-by":"crossref","unstructured":"Drach J., Angerler J., Schuster J., Thalhammer R., Jager U., Geissler K., Lechner K., Ludwig H., Huber H. Clonal chromosomal aberrations in plasma cells from patients with monoclonal gammopathy of undetermined significance (MGUS). Proc Am. Assoc. Cancer Res., 36:\u2008144\u20081995.","DOI":"10.1182\/blood.V86.10.3915.bloodjournal86103915"},{"key":"2022061620194287500_B71","unstructured":"Smadja N. V., Bastard C., Brgaudeau C. Primary plasma cell leukemia and multiple myeloma: one or two diseases according to the methodology. Blood, 94:\u20083607-3609, [Letter; comment]\u20081999."},{"key":"2022061620194287500_B72","doi-asserted-by":"crossref","unstructured":"Greipp P. R., Trendle M. C., Leong T., Oken M. M., Kay N. E., Van Ness B., Kyle R. A. Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma?. Leuk. Lymphoma., 35:\u200883-89, \u20081999.","DOI":"10.3109\/10428199909145707"},{"key":"2022061620194287500_B73","doi-asserted-by":"crossref","unstructured":"Orfao A., Garcia-Sanz R., Lopez-Berges M. C., Belen Vidriales M., Gonzalez M., Caballero M. D., San Miguel J. F. A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38\/propidium iodide double staining technique. Cytometry, 17:\u2008332-339, \u20081994.","DOI":"10.1002\/cyto.990170409"},{"key":"2022061620194287500_B74","doi-asserted-by":"crossref","unstructured":"Latreille J., Barlogie B., Dosik G., Johnston D. A., Drewinko B., Alexanian R. Cellular DNA content as a marker of human multiple myeloma. Blood, 55:\u2008403-408, \u20081980.","DOI":"10.1182\/blood.V55.3.403.bloodjournal553403"},{"key":"2022061620194287500_B75","doi-asserted-by":"crossref","unstructured":"Fonseca R., Debes-Marun C., Picken E., Dewald G., Bryant S., Winkler J., Blood E., Oken M. M., Santana-Da\u0301vila R., Gonza\u0301lez-Paz N., Kyle R., Gertz M., Dispenzieri A., Lacy M., Greipp P. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood, 102:\u20082562-2567, \u20082003.","DOI":"10.1182\/blood-2003-02-0493"},{"key":"2022061620194287500_B76","doi-asserted-by":"crossref","unstructured":"Smadja N. V., Leroux D., Soulier J., Dumont S., Arnould C., Taviaux S., Taillemite J. L., Bastard C. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid patients. Genes Chromosomes Cancer, 38:\u2008234-239, \u20082003.","DOI":"10.1002\/gcc.10275"},{"key":"2022061620194287500_B77","doi-asserted-by":"crossref","unstructured":"Perez-Simon J. A., Garcia-Sanz R., Tabernero M. D., Almeida J., Gonzalez M., Fernandez-Calvo J., Moro M. J., Hernandez J. M., San Miguel J. F., Orfao A. Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes. Blood, 91:\u20083366-3371, \u20081998.","DOI":"10.1182\/blood.V91.9.3366"},{"key":"2022061620194287500_B78","doi-asserted-by":"crossref","unstructured":"Smith L., Barlogie B., Alexanian R. Biclonal and hypodiploid multiple myeloma. Am. J. Med., 80:\u2008841-843, \u20081986.","DOI":"10.1016\/0002-9343(86)90625-X"},{"key":"2022061620194287500_B79","doi-asserted-by":"crossref","unstructured":"Calasanz M. J., Cigudosa J. C., Odero M. D., Garcia-Foncillas J., Marin J., Ardanaz M. T., Rocha E., Gullon A. Hypodiploidy and 22q11 rearrangements at diagnosis are associated with poor prognosis in patients with multiple myeloma. Br. J. Haematol., 98:\u2008418-425, \u20081997.","DOI":"10.1046\/j.1365-2141.1997.2443061.x"},{"key":"2022061620194287500_B80","doi-asserted-by":"crossref","unstructured":"Fassas A. B., Spencer T., Sawyer J., Zangari M., Lee C. K., Anaissie E., Muwalla F., Morris C., Barlogie B., Tricot G. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br. J. Haematol., 118:\u20081041-1047, \u20082002.","DOI":"10.1046\/j.1365-2141.2002.03757.x"},{"key":"2022061620194287500_B81","doi-asserted-by":"crossref","unstructured":"Drach J., Kaufmann H., Urbauer E., Schreiber S., Ackermann J., Huber H. The biology of multiple myeloma. J. Cancer Res. Clin. Oncol., 126:\u2008441-447, [Review]\u20082000.","DOI":"10.1007\/s004320050011"},{"key":"2022061620194287500_B82","unstructured":"Fonseca, R., Bailey, R., Ahmann, G., Aguayo, P., Jalal, S., Rajkumar, S., Kyle, R., Gertz, M., Dispenzieri, A., Lust, J., Lacy, M., Witzig, T., Greipp, P., and Dewald, G. Translocations involving 14q32 are common in patients with the monoclonal gammopathy of undetermined significance. Blood, in press, 2003."},{"key":"2022061620194287500_B83","doi-asserted-by":"crossref","unstructured":"Zojer N., Konigsberg R., Ackermann J., Fritz E., Dallinger S., Kromer E., Kaufmann H., Riedl L., Gisslinger H., Schreiber S., Heinz R., Ludwig H., Huber H., Drach J. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood, 95:\u20081925-1930, \u20082000.","DOI":"10.1182\/blood.V95.6.1925"},{"key":"2022061620194287500_B84","doi-asserted-by":"crossref","unstructured":"Facon T., Avet-Loiseau H., Guillerm G., Moreau P., Genevie\u0300ve F., Zandecki M., Lai\u0308 J., Leleu X., Jouet J., Bauters F., Harousseau J., Bataille R., Mary J. Y., Intergroupe Francophone du Myelome. Chromosome 13 abnormalities identified by FISH analysis and serum \u03b2-2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood, 97:\u20081566-1571, \u20082001.","DOI":"10.1182\/blood.V97.6.1566"},{"key":"2022061620194287500_B85","doi-asserted-by":"crossref","unstructured":"Carlebach M., Amiel A., Gaber E., Radnay J., Manor Y., Fejgin M., Lishner M. Multiple myeloma: monoallelic deletions of the tumor suppressor genes TP53 and RB1 in long-term follow-up. Cancer Genet. Cytogenet., 117:\u200857-60, \u20082000.","DOI":"10.1016\/S0165-4608(99)00144-2"},{"key":"2022061620194287500_B86","doi-asserted-by":"crossref","unstructured":"Shaughnessy J., Tian E., Sawyer J., Bumm K., Landes R., Badros A., Morris C., Tricot G., Epstein J., Barlogie B. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood, 96:\u20081505-1511, \u20082000.","DOI":"10.1182\/blood.V96.4.1505"},{"key":"2022061620194287500_B87","doi-asserted-by":"crossref","unstructured":"Desikan R., Barlogie B., Sawyer J., Ayers D., Tricot G., Badros A., Zangari M., Munshi N. C., Anaissie E., Spoon D., Siegel D., Jagannath S., Vesole D., Epstein J., Shaughnessy J., Fassas A., Lim S., Roberson P., Crowley J. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood, 95:\u20084008-4010, \u20082000.","DOI":"10.1182\/blood.V95.12.4008.012k03_4008_4010"},{"key":"2022061620194287500_B88","doi-asserted-by":"crossref","unstructured":"Shaughnessy J., Jr., Tian E., Sawyer J., McCoy J., Tricot G., Jacobson J., Anaissie E., Zangari M., Fassas A., Muwalla F., Morris C., Barlogie B. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br. J. Haematol., 120:\u200844-52, \u20082003.","DOI":"10.1046\/j.1365-2141.2003.03948.x"},{"key":"2022061620194287500_B89","doi-asserted-by":"crossref","unstructured":"Shaughnessy J., Jacobson J., Sawyer J., McCoy J., Fassas A., Zhan F., Bumm K., Epstein J., Anaissie E., Jagannath S., Vesole D., Siegel D., Desikan R., Munshi N., Badros A., Tian E., Zangari M., Tricot G., Crowley J., Barlogie B. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood, 101:\u20083849-3856, \u20082003.","DOI":"10.1182\/blood-2002-09-2873"},{"key":"2022061620194287500_B90","doi-asserted-by":"crossref","unstructured":"Tricot G., Sawyer J. R., Jagannath S., Desikan K. R., Siegel D., Naucke S., Mattox S., Bracy D., Munshi N., Barlogie B. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J. Clin. Oncol., 15:\u20082659-2666, \u20081997.","DOI":"10.1200\/JCO.1997.15.7.2659"},{"key":"2022061620194287500_B91","doi-asserted-by":"crossref","unstructured":"Moreau P., Facon T., Leleu X., Morineau N., Huyghe P., Harousseau J. L., Bataille R., Avet-Loiseau H. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood, 100:\u20081579-1583, \u20082002.","DOI":"10.1182\/blood-2002-03-0749"},{"key":"2022061620194287500_B92","doi-asserted-by":"crossref","unstructured":"Schreiber S., Ackermann J., Obermair A., Kaufmann H., Urbauer E., Aletaha K., Gisslinger H., Chott a., Huber H., Drach J. Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization. Br. J. Haematol., 110:\u2008605-609, \u20082000.","DOI":"10.1046\/j.1365-2141.2000.02248.x"},{"key":"2022061620194287500_B93","unstructured":"Bergsagel P. L., Chesi M., Brents L. A., Kuehl W. M. Translocations into IgH switch regions\u2014the genetic hallmark of multiple myeloma. Blood, 86:\u2008223-223, \u20081995."},{"key":"2022061620194287500_B94","doi-asserted-by":"crossref","unstructured":"Bergsagel P. L., Chesi M., Nardini E., Brents L. A., Kirby S. L., Kuehl W. M. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc. Natl. Acad. Sci. USA, 93:\u200813931-13936, \u20081996.","DOI":"10.1073\/pnas.93.24.13931"},{"key":"2022061620194287500_B95","doi-asserted-by":"crossref","unstructured":"Nishida K., Tamura A., Nakazawa N., Ueda Y., Abe T., Matsuda F., Kashima K., Taniwaki M. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood, 90:\u2008526-534, \u20081997.","DOI":"10.1182\/blood.V90.2.526.526_526_534"},{"key":"2022061620194287500_B96","doi-asserted-by":"crossref","unstructured":"Shou Y., Martelli M. L., Gabrea A., Qi Y., Brents L. A., Roschke A., Dewald G., Kirsch I. R., Bergsagel P. L., Kuehl W. M. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc. Natl. Acad. Sci. USA, 97:\u2008228-233, \u20082000.","DOI":"10.1073\/pnas.97.1.228"},{"key":"2022061620194287500_B97","doi-asserted-by":"crossref","unstructured":"Avet-Loiseau H., Gerson F., Magrangeas F., Minvielle S., Harousseau J. L., Bataille R. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood, 98:\u20083082-3086, \u20082001.","DOI":"10.1182\/blood.V98.10.3082"},{"key":"2022061620194287500_B98","doi-asserted-by":"crossref","unstructured":"Ried K., Finnis M., Hobson L., Mangelsdorf M., Dayan S., Nancarrow J. K., Woollatt E., Kremmidiotis G., Gardner A., Venter D., Baker E., Richards R. I. Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. Hum. Mol. Genet., 9:\u20081651-1663, \u20082000.","DOI":"10.1093\/hmg\/9.11.1651"},{"key":"2022061620194287500_B99","doi-asserted-by":"crossref","unstructured":"Krummel K. A., Roberts L. R., Kawakami M., Glover T. W., Smith D. I. The characterization of the common fragile site FRA16D and its involvement in multiple myeloma translocations. Genomics, 69:\u200837-46, \u20082000.","DOI":"10.1006\/geno.2000.6321"},{"key":"2022061620194287500_B100","doi-asserted-by":"crossref","unstructured":"Hallek M., Leif Bergsagel P., Anderson K. C. Multiple myeloma: increasing evidence for a multistep transformation process. Blood, 91:\u20083-21, \u20081998.","DOI":"10.1182\/blood.V91.1.3.3_3_21"},{"key":"2022061620194287500_B101","doi-asserted-by":"crossref","unstructured":"Willis T. G., Dyer M. J. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood, 96:\u2008808-822, \u20082000.","DOI":"10.1182\/blood.V96.3.808"},{"key":"2022061620194287500_B102","doi-asserted-by":"crossref","unstructured":"Avet-Loiseau H., Daviet A., Brigaudeau C., Callet-Bauchu E., Terre C., Lafage-Pochitaloff M., Desangles F., Ramond S., Talmant P., Bataille R. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique. Blood, 97:\u2008822-825, \u20082001.","DOI":"10.1182\/blood.V97.3.822"},{"key":"2022061620194287500_B103","doi-asserted-by":"crossref","unstructured":"Bergsagel P., Kuehl W. Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol Rev., 194:\u200896-104, \u20082003.","DOI":"10.1034\/j.1600-065X.2003.00052.x"},{"key":"2022061620194287500_B104","doi-asserted-by":"crossref","unstructured":"Shaughnessy J., Jr., Gabrea A., Qi Y., Brents L., Zhan F., Tian E., Sawyer J., Barlogie B., Bergsagel P. L., Kuehl M. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood, 98:\u2008217-223, \u20082001.","DOI":"10.1182\/blood.V98.1.217"},{"key":"2022061620194287500_B105","unstructured":"Malgeri U., Baldini L., Perfetti V., Fabris S., Vignarelli M. C., Colombo G., Lotti V., Compasso S., Bogni S., Lombardi L., Maiolo A. T., Neri A. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts. Cancer Res., 60:\u20084058-4061, \u20082000."},{"key":"2022061620194287500_B106","doi-asserted-by":"crossref","unstructured":"Chesi M., Bergsagel P. L., Brents L. A., Smith C. M., Gerhard D. S., Kuehl W. M. Dysregulation of cyclin D1 by translocation into an IgH \u03b3 switch region in two multiple myeloma cell lines. Blood, 88:\u2008674-681, \u20081996.","DOI":"10.1182\/blood.V88.2.674.bloodjournal882674"},{"key":"2022061620194287500_B107","doi-asserted-by":"crossref","unstructured":"Fonseca R., Witzig T. E., Gertz M. A., Kyle R. A., Hoyer J. D., Jalal S. M., Greipp P. R. Multiple myeloma and the translocation t(11;14)(q13;q32)\u2014a report on 13 cases. Br. J. Haematol., 101:\u2008296-301, \u20081998.","DOI":"10.1046\/j.1365-2141.1998.00700.x"},{"key":"2022061620194287500_B108","unstructured":"Harrison, C., Mazullo, H., Cheung, K., Mehta, A., Lachmann, H., Hawkins, P., and Orchard, K. Chromosomal abnormalities in systemic amyloidosis. In: Proceedings of the VIII International Myeloma Workshop, Banff, Alberta, Canada, 2001, p. P18."},{"key":"2022061620194287500_B109","unstructured":"Janssen J. W., Vaandrager J. W., Heuser T., Jauch A., Kluin P. M., Geelen E., Bergsagel P. L., Kuehl W. M., Drexler H. G., Otsuki T., Bartram C. R., Schuuring E. Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32). Blood, 95:\u20082691-2698, \u20082000."},{"key":"2022061620194287500_B110","doi-asserted-by":"crossref","unstructured":"Vaandrager J. W., Kluin P., Schuuring E. The t(11;14) (q13;q32) in multiple myeloma cell line KMS12 has its 11q13 breakpoint 330 kb centromeric from the cyclin D1 gene. Blood, 89:\u2008349-350, [Letter]\u20081997.","DOI":"10.1182\/blood.V89.1.349.349_349_349"},{"key":"2022061620194287500_B111","doi-asserted-by":"crossref","unstructured":"Meeus P., Stul M. S., Mecucci C., Cassiman J. J., Van den Berghe H. Molecular breakpoints of t(11;14)(q13;q32) in multiple myeloma. Cancer Genet Cytogenet., 83:\u200825-27, \u20081995.","DOI":"10.1016\/S0165-4608(94)00211-8"},{"key":"2022061620194287500_B112","doi-asserted-by":"crossref","unstructured":"Ronchetti D., Finelli P., Richelda R., Baldini L., Rocchi M., Viggiano L., Cuneo A., Bogni S., Fabris S., Lombardi L., Maiolo A., Neri A. Molecular analysis of 11q13 breakpoints in multiple myeloma. Blood, 93:\u20081330-1337, \u20081999.","DOI":"10.1182\/blood.V93.4.1330.404k04_1330_1337"},{"key":"2022061620194287500_B113","doi-asserted-by":"crossref","unstructured":"Raynaud S. D., Bekri S., Leroux D., Grosgeorge J., Klein B., Bastard C., Gaudray P., Simon M. P. Expanded range of 11q13 breakpoints with differing patterns of cyclin D1 expression in B-cell malignancies. Genes Chromosomes Cancer, 8:\u200880-87, \u20081993.","DOI":"10.1002\/gcc.2870080204"},{"key":"2022061620194287500_B114","doi-asserted-by":"crossref","unstructured":"Hoyer J. D., Hanson C. A., Fonseca R., Greipp P. R., Dewald G. W., Kurtin P. J. The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study. Am. J. Clin. Pathol., 113:\u2008831-837, \u20082000.","DOI":"10.1309\/4W8E-8F4K-BHUP-UBE7"},{"key":"2022061620194287500_B115","unstructured":"Vasef M. A., Medeiros L. J., Yospur L. S., Sun N. C., McCourty A., Brynes R. K. Cyclin D1 protein in multiple myeloma and plasmacytoma: an immunohistochemical study using fixed, paraffin-embedded tissue sections. Mod. Pathol., 10:\u2008927-932, \u20081997."},{"key":"2022061620194287500_B116","doi-asserted-by":"crossref","unstructured":"Rosenwald A., Wright G., Wiestner A., Chan W. C., Connors J. M., Campo E., Gascoyne R. D., Grogan T. M., Muller-Hermelink H. K., Smeland E. B., Chiorazzi M., Giltnane J. M., Hurt E. M., Zhao H., Averett L., Henrickson S., Yang L., Powell J., Wilson W. H., Jaffe E. S., Simon R., Klausner R. D., Montserrat E., Bosch F., Greiner T. C., Weisenburger D. D., Sanger W. G., Dave B. J., Lynch J. C., Vose J., Armitage J. O., Fisher R. I., Miller T. P., LeBlanc M., Ott G., Kvaloy S., Holte H., Delabie J., Staudt L. M. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell., 3:\u2008185-197, \u20082003.","DOI":"10.1016\/S1535-6108(03)00028-X"},{"key":"2022061620194287500_B117","doi-asserted-by":"crossref","unstructured":"Konigsberg R., Zojer N., Ackermann J., Kromer E., Kittler H., Fritz E., Kaufmann H., Nosslinger T., Riedl L., Gisslinger H., Jager U., Simonitsch I., Heinz R., Ludwig H., Huber H., Drach J. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J. Clin. Oncol., 18:\u2008804-812, \u20082000.","DOI":"10.1200\/JCO.2000.18.4.804"},{"key":"2022061620194287500_B118","doi-asserted-by":"crossref","unstructured":"Robillard N., Avet-Loiseau H., Garand R., Moreau P., Pineau D., Rapp M-J., Harousseau J-L., Bataille R. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood, 102:\u20081070-1071, \u20082003.","DOI":"10.1182\/blood-2002-11-3333"},{"key":"2022061620194287500_B119","doi-asserted-by":"crossref","unstructured":"Avet-Loiseau H., Garand R., Lode L., Harousseau J-L., Bataille R. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood, 101:\u20081570-1571, \u20082003.","DOI":"10.1182\/blood-2002-08-2436"},{"key":"2022061620194287500_B120","doi-asserted-by":"crossref","unstructured":"Chesi M., Nardini E., Lim R., Smith K., Kuehl W., Bergsagel P. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH\/MMSET hybrid transcripts. Blood, 92:\u20083025-3034, \u20081998.","DOI":"10.1182\/blood.V92.9.3025.421k53_3025_3034"},{"key":"2022061620194287500_B121","doi-asserted-by":"crossref","unstructured":"Richelda R., Ronchetti D., Baldini L., Cro L., Viggiano L., Marzella R., Rocchi M., Otsuki T., Lombardi L., Maiolo A. T., Neri A. A novel chromosomal translocation t(4;14)(p16.3;q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood, 90:\u20084062-4070, \u20081997.","DOI":"10.1182\/blood.V90.10.4062"},{"key":"2022061620194287500_B122","doi-asserted-by":"crossref","unstructured":"Intini D., Baldini L., Fabris S., Lombardi L., Ciceri G., Maiolo A. T., Neri A. Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). Br. J. Haematol., 114:\u2008362-364, \u20082001.","DOI":"10.1046\/j.1365-2141.2001.02957.x"},{"key":"2022061620194287500_B123","doi-asserted-by":"crossref","unstructured":"Chesi M., Brents L. A., Ely S. A., Bais C., Robbiani D. F., Mesri E. A., Kuehl W. M., Bergsagel P. L. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood, 97:\u2008729-736, \u20082001.","DOI":"10.1182\/blood.V97.3.729"},{"key":"2022061620194287500_B124","doi-asserted-by":"crossref","unstructured":"Ronchetti D., Greco A., Compasso S., Colombo G., Dell\u2019Era P., Otsuki T., Lombardi L., Neri A. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene, 20:\u20083553-3562, \u20082001.","DOI":"10.1038\/sj.onc.1204465"},{"key":"2022061620194287500_B125","doi-asserted-by":"crossref","unstructured":"Perfetti V., Coluccia A., Intini D., Malgeri U., Colli Vignarelli M., Casarini S., Merlini G., Neri A. Translocation t(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis. Leukemia (Baltimore), 158:\u20081599-1603, \u20082001.","DOI":"10.1016\/S0002-9440(10)64115-6"},{"key":"2022061620194287500_B126","doi-asserted-by":"crossref","unstructured":"Hanamura I., Iida S., Akano Y., Hayami Y., Kato M., Miura K., Harada S., Banno S., Wakita A., Kiyoi H., Naoe T., Shimizu S., Sonta S. I., Nitta M., Taniwaki M., Ueda R. Ectopic expression of MAFB gene in human myeloma cells carrying (14;20)(q32;q11) chromosomal translocations. Jpn J Cancer Res., 92:\u2008638-644, \u20082001.","DOI":"10.1111\/j.1349-7006.2001.tb01142.x"},{"key":"2022061620194287500_B127","doi-asserted-by":"crossref","unstructured":"Iida S., Rao P. H., Butler M., Corradini P., Boccadoro M., Klein B., Chaganti R. S., Dalla-Favera R. Deregulation of MUM1\/IRF4 by chromosomal translocation in multiple myeloma. Nat. Genet., 17:\u2008226-230, \u20081997.","DOI":"10.1038\/ng1097-226"},{"key":"2022061620194287500_B128","doi-asserted-by":"crossref","unstructured":"Yoshida S., Nakazawa N., Iida S., Hayami Y., Sato S., Wakita A., Shimizu S., Taniwaki M., Ueda R. Detection of MUM1\/IRF4-IgH fusion in multiple myeloma. Leukemia (Baltimore), 13:\u20081812-1816, \u20081999.","DOI":"10.1038\/sj.leu.2401563"},{"key":"2022061620194287500_B129","doi-asserted-by":"crossref","unstructured":"Liu P., Leong T., Quam L., Billadeau D., Kay N. E., Greipp P., Kyle R. A., Oken M. M., Van Ness B. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood, 88:\u20082699-2706, \u20081996.","DOI":"10.1182\/blood.V88.7.2699.bloodjournal8872699"},{"key":"2022061620194287500_B130","doi-asserted-by":"crossref","unstructured":"Bezieau S., Devilder M. C., Avet-Loiseau H., Mellerin M. P., Puthier D., Pennarun E., Rapp M. J., Harousseau J. L., Moisan J. P., Bataille R. High incidence of N- and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum. Mutat., 18:\u2008212-224, \u20082001.","DOI":"10.1002\/humu.1177"},{"key":"2022061620194287500_B131","doi-asserted-by":"crossref","unstructured":"Bezieau S., Avet-Loiseau H., Moisan J. P., Bataille R. Activating Ras mutations in patients with plasma-cell disorders: a reappraisal. Blood, 100:\u20081101-1102, \u20082003.","DOI":"10.1182\/blood-2002-03-0795"},{"key":"2022061620194287500_B132","doi-asserted-by":"crossref","unstructured":"Corradini P., Ladetto M., Voena C., Palumbo A., Inghirami G., Knowles D. M., Boccadoro M., Pileri A. Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. Blood, 81:\u20082708-2713, \u20081993.","DOI":"10.1182\/blood.V81.10.2708.bloodjournal81102708"},{"key":"2022061620194287500_B133","doi-asserted-by":"crossref","unstructured":"Neri A., Murphy J. P., Cro L., Ferrero D., Tarella C., Baldini L., Dalla-Favera R. Ras oncogene mutation in multiple myeloma. J. Exp. Med., 170:\u20081715-1725, \u20081989.","DOI":"10.1084\/jem.170.5.1715"},{"key":"2022061620194287500_B134","unstructured":"Matozaki S., Nakagawa T., Nakao Y., Fujita T. RAS gene mutations in multiple myeloma and related monoclonal gammopathies. Kobe J. Med. Sci., 37:\u200835-45, \u20081991."},{"key":"2022061620194287500_B135","doi-asserted-by":"crossref","unstructured":"Crowder C., Kopantzev E., Williams K., Lengel C., Miki T., Rudikoff S. An unusual H-Ras mutant isolated from a human multiple myeloma line leads to transformation and factor-independent cell growth. Oncogene, 22:\u2008649-659, \u20082003.","DOI":"10.1038\/sj.onc.1206180"},{"key":"2022061620194287500_B136","doi-asserted-by":"crossref","unstructured":"Drach J., Ackermann J., Fritz E., Kromer E., Schuster R., Gisslinger H., DeSantis M., Zojer N., Fiegl M., Roka S., Schuster J., Heinz R., Ludwig H., Huber H. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood, 92:\u2008802-809, \u20081998.","DOI":"10.1182\/blood.V92.3.802"},{"key":"2022061620194287500_B137","doi-asserted-by":"crossref","unstructured":"Schultheis B., Kramer A., Willer A., Hegenbart U., Goldschmidt H., Hehlmann R. Analysis of p73 and p53 gene deletions in multiple myeloma. Leukemia (Baltimore), 13:\u20082099-2103, \u20081999.","DOI":"10.1038\/sj.leu.2401609"},{"key":"2022061620194287500_B138","unstructured":"Mazars G. R., Portier M., Zhang X. G., Jourdan M., Bataille R., Theillet C., Klein B. Mutations of the p53 gene in human myeloma cell lines. Oncogene, 7:\u20081015-1018, \u20081992."},{"key":"2022061620194287500_B139","unstructured":"Corradini P., Inghirami G., Astolfi M., Ladetto M., Voena C., Ballerini P., Gu W., Nilsson K., Knowles D. M., Boccadoro M., Pileri A., Dalla-Favera R. Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. Leukemia (Baltimore), 8:\u2008758-767, \u20081994."},{"key":"2022061620194287500_B140","doi-asserted-by":"crossref","unstructured":"Neri A., Baldini L., Trecca D., Cro L., Polli E., Maiolo A. T. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood, 81:\u2008128-135, \u20081993.","DOI":"10.1182\/blood.V81.1.128.bloodjournal811128"},{"key":"2022061620194287500_B141","doi-asserted-by":"crossref","unstructured":"Preudhomme C., Facon T., Zandecki M., Vanrumbeke M., Lai J. L., Nataf E., Loucheux L. M. H., Kerckaert J. P., Fenaux P. Rare occurrence of p53 gene mutations in multiple myeloma. Br. J. Haematol., 81:\u2008440-443, \u20081992.","DOI":"10.1111\/j.1365-2141.1992.tb08253.x"},{"key":"2022061620194287500_B142","doi-asserted-by":"crossref","unstructured":"Ackermann J., Meidlinger P., Zojer N., Gisslinger H., Ludwig H., Huber H., Drach J. Absence of p53 deletions in bone marrow plasma cells of patients with monoclonal gammopathy of undetermined significance. Br. J. Haematol., 103:\u20081161-1163, \u20081998.","DOI":"10.1046\/j.1365-2141.1998.01124.x"},{"key":"2022061620194287500_B143","doi-asserted-by":"crossref","unstructured":"Teoh G., Urashima M., Ogata A., Chauhan D., DeCaprio J. A., Treon S. P., Schlossman R. L., Anderson K. C. MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells. Blood, 90:\u20081982-1992, \u20081997.","DOI":"10.1182\/blood.V90.5.1982"},{"key":"2022061620194287500_B144","doi-asserted-by":"crossref","unstructured":"Potter M. Perspectives on the origins of multiple myeloma and plasmacytomas in mice. Hematol. Oncol. Clin. North Am., 6:\u2008211-223, \u20081992.","DOI":"10.1016\/S0889-8588(18)30340-X"},{"key":"2022061620194287500_B145","unstructured":"Gado K., Silva S., Paloczi K., Domjan G., Falus A. Mouse plasmacytoma: an experimental model of human multiple myeloma. Haematologica, 86:\u2008227-236, [Review]\u20082001."},{"key":"2022061620194287500_B146","doi-asserted-by":"crossref","unstructured":"Zhang S-L., DuBois W., Ramsay E. S., Bliskovski V., Morse H. C., III, Taddesse-Heath L., Vass W. C., DePinho R. A., Mock B. A. Efficiency alleles of the Pctr1 modifier locus for plasmacytoma susceptibility. Mol. Cell. Biol., 21:\u2008310-318, \u20082001.","DOI":"10.1128\/MCB.21.1.310-318.2001"},{"key":"2022061620194287500_B147","doi-asserted-by":"crossref","unstructured":"Dilworth D., Liu L., Stewart A. K., Berenson J. R., Lassam N., Hogg D. Germline CDKN2A mutation implicated in predisposition to multiple myeloma. Blood, 95:\u20081869-1871, \u20082000.","DOI":"10.1182\/blood.V95.5.1869.005k09_1869_1871"},{"key":"2022061620194287500_B148","doi-asserted-by":"crossref","unstructured":"Gonzalez M., Mateos M. V., Garcia-Sanz R., Balanzategui A., Lopez-Perez R., Chillon M. C., Gonzalez D., Alaejos I., San Miguel J. F. De novo methylation of tumor suppressor gene p16\/INK4a is a frequent finding in multiple myeloma patients at diagnosis. Leukemia (Baltimore), 14:\u2008183-187, \u20082000.","DOI":"10.1038\/sj.leu.2401617"},{"key":"2022061620194287500_B149","doi-asserted-by":"crossref","unstructured":"Uchida T., Kinoshita T., Ohno T., Ohashi H., Nagai H., Saito H. Hypermethylation of p16 INK4A gene promoter during the progression of plasma cell dyscrasia. Leukemia (Baltimore), 15:\u2008157-165, \u20082001.","DOI":"10.1038\/sj.leu.2401991"},{"key":"2022061620194287500_B150","doi-asserted-by":"crossref","unstructured":"Ng M. H., Wong I. H., Lo K. W. DNA methylation changes and multiple myeloma. Leuk. Lymphoma, 34:\u2008463-472, [Review]\u20081999.","DOI":"10.3109\/10428199909058473"},{"key":"2022061620194287500_B151","unstructured":"Lo Y. M., Wong I. H., Zhang J., Tein M. S., Ng M. H., Hjelm N. M. Quantitative analysis of aberrant p16 methylation using real-time quantitative methylation-specific polymerase chain reaction. Cancer Res., 59:\u20083899-3903, \u20081999."},{"key":"2022061620194287500_B152","doi-asserted-by":"crossref","unstructured":"Arora T., Jelinek D. F. Differential myeloma cell responsiveness to interferon-\u03b1 correlates with differential induction of p19(Ink4d) and cyclin D2 expression. J. Biol. Chem., 273:\u200811799-11805, \u20081998.","DOI":"10.1074\/jbc.273.19.11799"},{"key":"2022061620194287500_B153","doi-asserted-by":"crossref","unstructured":"Mateos M. V., Garcia-Sanz R., Lopez-Perez R., Moro M. J., Ocio E., Hernandez J., Megido M., Caballero M. D., Fernandez-Calvo J., Barez A., Almeida J., Orfao A., Gonzalez M., San Miguel J. F. Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br. J. Haematol., 118:\u20081034-1040, \u20082002.","DOI":"10.1046\/j.1365-2141.2002.03749.x"},{"key":"2022061620194287500_B154","doi-asserted-by":"crossref","unstructured":"Guillerm G., Gyan E., Wolowiec D., Facon T., Avet-Loiseau H., Kuliczkowski K., Bauters F., Fenaux P., Quesnel B. p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood, 98:\u2008244-246, \u20082001.","DOI":"10.1182\/blood.V98.1.244"},{"key":"2022061620194287500_B155","doi-asserted-by":"crossref","unstructured":"Morse L., Chen D., Franklin D., Xiong Y., Chen-Kiang S. Induction of cell cycle arrest and B cell terminal differentiation by CDK inhibitor p18(INK4c) and IL-6. Immunity, 6:\u200847-56, \u20081997.","DOI":"10.1016\/S1074-7613(00)80241-1"},{"key":"2022061620194287500_B156","doi-asserted-by":"crossref","unstructured":"Kulkarni M. S., Daggett J. L., Bender T. P., Kuehl W. M., Bergsagel P. L., Williams M. E. Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopicp18 expression inhibits growth and induces apoptosis. Leukemia (Baltimore), 16:\u2008127-134, \u20082002.","DOI":"10.1038\/sj.leu.2402328"},{"key":"2022061620194287500_B157","doi-asserted-by":"crossref","unstructured":"Zandecki M., Facon T., Preudhomme C., Vanrumbeke M., Vachee A., Quesnel B., Lai J. L., Cosson A., Fenaux P. The retinoblastoma gene (RB-1) status in multiple myeloma: a report on 35 cases. Leuk Lymphoma, 18:\u2008497-503, \u20081995.","DOI":"10.3109\/10428199509059651"},{"key":"2022061620194287500_B158","doi-asserted-by":"crossref","unstructured":"Juge-Morineau N., Harousseau J. L., Amiot M., Bataille R. The retinoblastoma susceptibility gene RB-1 in multiple myeloma. Leuk. Lymphoma, 24:\u2008229-237, [Review]\u20081997.","DOI":"10.3109\/10428199709039011"},{"key":"2022061620194287500_B159","doi-asserted-by":"crossref","unstructured":"Hyun T., Yam A., Pece S., Xie X., Zhang J., Miki T., Gutkind J. S., Li W. Loss of PTEN expression leading to high Akt activation in human multiple myelomas. Blood, 96:\u20083560-3568, \u20082000.","DOI":"10.1182\/blood.V96.10.3560.h8003560_3560_3568"},{"key":"2022061620194287500_B160","doi-asserted-by":"crossref","unstructured":"Ge N., Rudikoff S. Expression of PTEN in PTEN-deficient multiple myeloma cells abolishes tumor growth in vivo. Oncogene, 19:\u20084091-4095, \u20082000.","DOI":"10.1038\/sj.onc.1203801"},{"key":"2022061620194287500_B161","doi-asserted-by":"crossref","unstructured":"Crews S., Barth R., Hood L., Prehn J., Calame K. Mouse c-myc oncogene is located on chromosome 15 and translocated to chromosome 12 in plasmacytomas. Science (Wash. DC), 218:\u20081319-1321, \u20081982.","DOI":"10.1126\/science.7146913"},{"key":"2022061620194287500_B162","doi-asserted-by":"crossref","unstructured":"Stanton L. W., Watt R., Marcu K. B. Translocation, breakage and truncated transcripts of c-myc oncogene in murine plasmacytomas. Nature (Lond.), 303:\u2008401-406, \u20081983.","DOI":"10.1038\/303401a0"},{"key":"2022061620194287500_B163","doi-asserted-by":"crossref","unstructured":"Keath E. J., Kelekar A., Cole M. D. Transcriptional activation of the translocated c-myc oncogene in mouse plasmacytomas: similar RNA levels in tumor and proliferating normal cells. Cell, 37:\u2008521-528, \u20081984.","DOI":"10.1016\/0092-8674(84)90382-9"},{"key":"2022061620194287500_B164","doi-asserted-by":"crossref","unstructured":"Piccoli S. P., Caimi P. G., Cole M. D. A conserved sequence at c-myc oncogene chromosomal translocation breakpoints in plasmacytomas. Nature (Lond.), 310:\u2008327-330, \u20081984.","DOI":"10.1038\/310327a0"},{"key":"2022061620194287500_B165","doi-asserted-by":"crossref","unstructured":"Erikson J., Miller D. A., Miller O. J., Abcarian P. W., Skurla R. M., Mushinski J. F., Croce C. M. The c-myc oncogene is translocated to the involved chromosome 12 in mouse plasmacytoma. Proc. Natl. Acad. Sci. USA, 82:\u20084212-4216, \u20081985.","DOI":"10.1073\/pnas.82.12.4212"},{"key":"2022061620194287500_B166","doi-asserted-by":"crossref","unstructured":"Adams J. M., Harris A. W., Pinkert C. A., Corcoran L. M., Alexander W. S., Cory S., Palmiter R. D., Brinster R. L. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature (Lond.), 318:\u2008533-538, \u20081985.","DOI":"10.1038\/318533a0"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/64\/4\/1546\/2522240\/zch00404001546.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/64\/4\/1546\/2522240\/zch00404001546.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T21:34:20Z","timestamp":1655415260000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/64\/4\/1546\/512173\/Genetics-and-Cytogenetics-of-Multiple-MyelomaA"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2,15]]},"references-count":166,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2004,2,18]]},"published-print":{"date-parts":[[2004,2,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-03-2876","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,2,15]]}}}